Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants

69
23
Favorite

Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants

seekingalpha2021-05-03

(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（23）

MayTan
·2021-05-04
Noted
Reply
1
Report
Windfall10
·2021-05-04
Ok
Reply
1
Report
MinLee
·2021-05-03
Good
Reply
Like
Report
Deetigger
·2021-05-03
Yesssss
Reply
Like
Report
KTran
·2021-05-03
Amazing ?
Reply
1
Report
Blackk
·2021-05-03
Ok
Reply
2
Report
alvinpmc
·2021-05-03
Fly
Reply
Like
Report
btzm1991
·2021-05-03
All in!!!
Reply
Like
Report
大家好我是王剛88888
·2021-05-03
Think The CEO is Indian. But not sure it will work on India varient. India is now hopeless
Reply
Like
Report
BRK
·2021-05-03
Thanks for sharing !
Reply
1
Report
Ryanval2007
·2021-05-03
Yes
Reply
Like
Report
weiliang
·2021-05-03
Nice
Reply
Like
Report
weiliang
·2021-05-03
Nice
Reply
Like
Report
nujnay
·2021-05-03
??
Reply
Like
Report
Ivylow
·2021-05-03
Read
Reply
1
Report
Fold Replies
- Ivylow:
  Read
  2021-05-07
  Reply
  Report
- ElunMask:
  Cool
  2021-05-03
  Reply
  Report
- ElunMask:
  Haha
  2021-05-03
  Reply
  Report
JackieZHD
·2021-05-03
Test post
Reply
Like
Report
Yugeshwran
·2021-05-03
Ocgn got PR today. But the deep
Reply
1
Report
rsu
·2021-05-03
Amazing, but sold too early?
Reply
1
Report
Fold Replies
- Stephanie58:
  Too bad
  2021-05-03
  Reply
  Report
S土豪熊貓G
·2021-05-03
Yes, finally and FDA ApprovalThis week! Don’t wait anymore.Catch the train and buy the last few tickets does it will sore to rocket. I see you at the Moon pees.
Reply
Like
Report
KCLow
·2021-05-03
Happy go lucky
Reply
3
Report
Fold Replies
- JoZeC:
  Yay
  2021-05-03
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1102550859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-03 21:17","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1102550859","market":"us","top_or_hot":-1,"title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","media":"seekingalpha","content":"<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","article_id":"1102550859","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","pubTimestamp":1620047876,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"Covaxin对三种新冠病毒变种的潜在有效性使Ocugen股价上涨13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":106190712,"gmtCreate":1620091518536,"gmtModify":1704338496750,"author":{"id":"3573019619191060","authorId":"3573019619191060","name":"MayTan","avatar":"https://static.tigerbbs.com/808e2dbe5d70103ebf181c1496a31644","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"3573019619191060","authorIdStr":"3573019619191060"},"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106190712","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":106991268,"gmtCreate":1620082686954,"gmtModify":1704338236903,"author":{"id":"3581834933175279","authorId":"3581834933175279","name":"Windfall10","avatar":"https://static.tigerbbs.com/ff7812fc4f6d030648888d978fc206d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581834933175279","authorIdStr":"3581834933175279"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106991268","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108783555,"gmtCreate":1620054714877,"gmtModify":1704338010995,"author":{"id":"3574943172077831","authorId":"3574943172077831","name":"MinLee","avatar":"https://static.tigerbbs.com/b8e65b4867fb510a33338f7ebccddab7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574943172077831","authorIdStr":"3574943172077831"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108783555","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108715962,"gmtCreate":1620054282256,"gmtModify":1704338003219,"author":{"id":"3581460950323008","authorId":"3581460950323008","name":"Deetigger","avatar":"https://static.tigerbbs.com/671d22871e373eaf1470a796efacc49a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581460950323008","authorIdStr":"3581460950323008"},"htmlText":"Yesssss","listText":"Yesssss","text":"Yesssss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108715962","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108799181,"gmtCreate":1620052613343,"gmtModify":1704337967240,"author":{"id":"3579231234364241","authorId":"3579231234364241","name":"KTran","avatar":"https://static.tigerbbs.com/9e08e7adfbdfce83dc70663014994240","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579231234364241","authorIdStr":"3579231234364241"},"htmlText":"Amazing ?&nbsp;","listText":"Amazing ?&nbsp;","text":"Amazing ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108799181","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108471198,"gmtCreate":1620051534114,"gmtModify":1704337942749,"author":{"id":"3572770726668540","authorId":"3572770726668540","name":"Blackk","avatar":"https://static.tigerbbs.com/93d9bfa23cdea8af3308e34dedf35d9e","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3572770726668540","authorIdStr":"3572770726668540"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108471198","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108473038,"gmtCreate":1620051483924,"gmtModify":1704337940316,"author":{"id":"3571790492386093","authorId":"3571790492386093","name":"alvinpmc","avatar":"https://static.tigerbbs.com/35834faf01a49827f2961d3ee9bf667a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3571790492386093","authorIdStr":"3571790492386093"},"htmlText":"Fly&nbsp;","listText":"Fly&nbsp;","text":"Fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108473038","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108470062,"gmtCreate":1620051399456,"gmtModify":1704337937241,"author":{"id":"3576672486270158","authorId":"3576672486270158","name":"btzm1991","avatar":"https://static.tigerbbs.com/e069fa6dd8de7190f5729f91d4cdcab4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3576672486270158","authorIdStr":"3576672486270158"},"htmlText":"All in!!!&nbsp;","listText":"All in!!!&nbsp;","text":"All in!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108470062","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108449803,"gmtCreate":1620050974302,"gmtModify":1704337924125,"author":{"id":"3568341343298894","authorId":"3568341343298894","name":"大家好我是王剛88888","avatar":"https://static.tigerbbs.com/d84a1454474c28ae62985e96195561d3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568341343298894","authorIdStr":"3568341343298894"},"htmlText":"Think The CEO is Indian. But not sure it will work on India varient. India is now hopeless","listText":"Think The CEO is Indian. But not sure it will work on India varient. India is now hopeless","text":"Think The CEO is Indian. But not sure it will work on India varient. India is now hopeless","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108449803","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108453030,"gmtCreate":1620050627420,"gmtModify":1704337911425,"author":{"id":"3582932849391351","authorId":"3582932849391351","name":"BRK","avatar":"https://static.tigerbbs.com/c56bf36da3f318973d4e98a59e9d07e8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582932849391351","authorIdStr":"3582932849391351"},"htmlText":"Thanks for sharing !&nbsp;","listText":"Thanks for sharing !&nbsp;","text":"Thanks for sharing !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108453030","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108427551,"gmtCreate":1620050550873,"gmtModify":1704337909308,"author":{"id":"3582010571984381","authorId":"3582010571984381","name":"Ryanval2007","avatar":"https://static.tigerbbs.com/56e4ec2fa88bc5dc5b36c83b42a63ba1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582010571984381","authorIdStr":"3582010571984381"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108427551","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108465405,"gmtCreate":1620049885107,"gmtModify":1704337890931,"author":{"id":"3574098880126065","authorId":"3574098880126065","name":"weiliang","avatar":"https://static.tigerbbs.com/a18c96c45a800a16734570968277654b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574098880126065","authorIdStr":"3574098880126065"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108465405","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108465294,"gmtCreate":1620049879018,"gmtModify":1704337890770,"author":{"id":"3574098880126065","authorId":"3574098880126065","name":"weiliang","avatar":"https://static.tigerbbs.com/a18c96c45a800a16734570968277654b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574098880126065","authorIdStr":"3574098880126065"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108465294","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108466040,"gmtCreate":1620049750480,"gmtModify":1704337887534,"author":{"id":"3562385137512604","authorId":"3562385137512604","name":"nujnay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562385137512604","authorIdStr":"3562385137512604"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108466040","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108489139,"gmtCreate":1620049294121,"gmtModify":1704337868420,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"Read&nbsp;","listText":"Read&nbsp;","text":"Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/108489139","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4245648,"gmtCreate":1620341882783,"gmtModify":1680787355459,"authorId":3582161778784599,"author":{"id":3582161778784599,"idStr":"3582161778784599","authorId":3582161778784599,"name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108489139,"type":1,"supId":0,"prevId":0,"content":"Read","text":"Read","html":"Read"},{"id":4209873,"gmtCreate":1620049451664,"gmtModify":1680786796410,"authorId":3579673345882908,"author":{"id":3579673345882908,"idStr":"3579673345882908","authorId":3579673345882908,"name":"ElunMask","avatar":"https://static.tigerbbs.com/4561a4b19c908bdc775c4daf68fb2fc6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108489139,"type":1,"supId":4209859,"prevId":0,"content":"<u>Cool</u>","text":"<u>Cool</u>","html":"<u>Cool</u>"},{"id":4209859,"gmtCreate":1620049427059,"gmtModify":1680786789219,"authorId":3579673345882908,"author":{"id":3579673345882908,"idStr":"3579673345882908","authorId":3579673345882908,"name":"ElunMask","avatar":"https://static.tigerbbs.com/4561a4b19c908bdc775c4daf68fb2fc6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108489139,"type":1,"supId":0,"prevId":0,"content":"<u>Haha</u>","text":"<u>Haha</u>","html":"<u>Haha</u>"}],"langContent":"EN"},{"id":108413487,"gmtCreate":1620048983949,"gmtModify":1704337856599,"author":{"id":"3581907469449792","authorId":"3581907469449792","name":"JackieZHD","avatar":"https://static.tigerbbs.com/4d330d0f95f1d65c544a2ce6b869c061","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581907469449792","authorIdStr":"3581907469449792"},"htmlText":"Test post","listText":"Test post","text":"Test post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108413487","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108435001,"gmtCreate":1620048661903,"gmtModify":1704337848768,"author":{"id":"3571310554141451","authorId":"3571310554141451","name":"Yugeshwran","avatar":"https://static.tigerbbs.com/3949d78b0c94a8c083801653cb482499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571310554141451","authorIdStr":"3571310554141451"},"htmlText":"Ocgn got PR today. But the deep","listText":"Ocgn got PR today. But the deep","text":"Ocgn got PR today. But the deep","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108435001","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108436775,"gmtCreate":1620048594097,"gmtModify":1704337847476,"author":{"id":"3569664437904571","authorId":"3569664437904571","name":"rsu","avatar":"https://static.tigerbbs.com/83c6d60ee50dc6f7f51540297717391b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569664437904571","authorIdStr":"3569664437904571"},"htmlText":"Amazing, but sold too early?","listText":"Amazing, but sold too early?","text":"Amazing, but sold too early?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/108436775","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4209719,"gmtCreate":1620048695969,"gmtModify":1680786782611,"authorId":3582023311610406,"author":{"id":3582023311610406,"idStr":"3582023311610406","authorId":3582023311610406,"name":"Stephanie58","avatar":"https://static.tigerbbs.com/3ad2409c4debb23bdfeaf6c92729dba5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108436775,"type":1,"supId":0,"prevId":0,"content":"Too bad","text":"Too bad","html":"Too bad"}],"langContent":"EN"},{"id":108438081,"gmtCreate":1620048376643,"gmtModify":1704337843916,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Yes, finally and FDA ApprovalThis week!&nbsp;&nbsp;Don’t wait anymore.Catch the train and buy the last few tickets does it will sore&nbsp;to rocket. I see you at the Moon pees.&nbsp;","listText":"Yes, finally and FDA ApprovalThis week!&nbsp;&nbsp;Don’t wait anymore.Catch the train and buy the last few tickets does it will sore&nbsp;to rocket. I see you at the Moon pees.&nbsp;","text":"Yes, finally and FDA ApprovalThis week! Don’t wait anymore.Catch the train and buy the last few tickets does it will sore to rocket. I see you at the Moon pees.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108438081","repostId":1102550859,"repostType":2,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108433758,"gmtCreate":1620048264874,"gmtModify":1704337842599,"author":{"id":"3572259982642808","authorId":"3572259982642808","name":"KCLow","avatar":"https://static.tigerbbs.com/63de208a8717dc673d26734eaa8f9ecb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3572259982642808","authorIdStr":"3572259982642808"},"htmlText":"Happy go lucky","listText":"Happy go lucky","text":"Happy go lucky","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/108433758","repostId":1102550859,"repostType":4,"repost":{"id":"1102550859","kind":"news","pubTimestamp":1620047876,"share":"https://ttm.financial/m/news/1102550859?lang=&edition=fundamental","pubTime":"2021-05-03 21:17","market":"us","language":"en","title":"Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants","url":"https://stock-news.laohu8.com/highlight/detail?id=1102550859","media":"seekingalpha","summary":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potenti","content":"<p>(May&nbsp;3)&nbsp;Ocugen&nbsp;announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.</p><p>Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.</p><p>Trials conducted by&nbsp;Indian Council of Medical Research&nbsp;show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.</p><p>Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.</p><p>OCGN shares&nbsp;up 13% premarket&nbsp;trading at $14.31. YTD growth in Ocugen share price is&nbsp;~600%.</p><p><img src=\"https://static.tigerbbs.com/30fc04238a986c2bd9cb1b0655f0043b\" tg-width=\"633\" tg-height=\"479\"></p><p>Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen's shares rise 13% on potential effectiveness of Covaxin in three COVID-19 variants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/news/3689160-ocugens-ocgn-shares-rise-on-potential-effectiveness-of-covaxin-in-covid-19-variants","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1102550859","content_text":"(May 3) Ocugen announcesthat in a new study, scientists have found that Covaxin demonstrated potential effectiveness against the Brazil variantof SARS-CoV-2, B.1.128.2.Previous studies have also suggested that Covaxin was effective against the U.K. variant, B.1.1.7, as well as theIndian double mutant variant, B.1.617.Trials conducted by Indian Council of Medical Research show Covaxin-vaccinated sera effectively neutralized variants in an in-vitro plaque reduction neutralization assay.Recently, in second interim results of Phase 3 trial, Covaxin showed 78% overall efficacy and100% in severe COVID-19 disease.OCGN shares up 13% premarket trading at $14.31. YTD growth in Ocugen share price is ~600%.Recently, CEO Dr. Shankar Musunuri hintedemergency use authorization for COVID-19 vaccine in U.S.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4209659,"gmtCreate":1620048284613,"gmtModify":1680786784031,"authorId":3554793302594739,"author":{"id":3554793302594739,"idStr":"3554793302594739","authorId":3554793302594739,"name":"JoZeC","avatar":"https://static.tigerbbs.com/e9743c4e710525cb8e9bca9204682bb9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":108433758,"type":1,"supId":0,"prevId":0,"content":"Yay","text":"Yay","html":"Yay"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":69,"commentSize":23,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}